Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 40 years' experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept and dose response in patients, cardiovascular safety assessments (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. External partnerships in North America, Europe and Asia deliver complete solutions for clients’ needs. For more information please visit www.celerion.com.
Celerion is the largest global early clinical research provider, with over 40 years' experience and three facilities globally.
Celerion offers the largest global Phase I and II clinical operations networks in the industry with over 600 beds (24 in-hospital).
Data Management and Biometrics at Celerion bridges the gap between medical practice and laboratory science by assessing the safety of drug products to maximize drug effects and minimize side effects.
Celerion's scientist design efficient, scientifically sound clinical studies; analyze and interpret data from these studies; and use the knowledge obtained to design the next study in the drug-development cycle.
Celerion has the experience and capacity to exceed clients’ bioanalytical expectations from method development and validation through rapid sample analysis supporting discovery through late stage clinical studies.
With 40 years of experience working with large and small molecules, Celerion uses the most advanced technologies and strategies to ensure on-time delivery of high-quality data. Celerion has two strategically placed bioanalytical laboratories in Zürich Switzerland and Lincoln, Nebraska USA.
Global SOPs and a harmonized electronic laboratory notebook system enable easy assay transfer between bioanalytical laboratories and ensure compliance with internal and regulated quality standards. The global electronic laboratory notebook system standardizes bioanalytical processes and improves documentation consistency, providing faster access to data on a centralized data repository.
Celerion's Drug Development Services helps pharmaceutical and biotechnology companies demonstrate early evidence of their compounds' clinical efficacy and tolerance in humans.
The knowledge and leadership of highly trained scientists enable clients to design and carry out comprehensive development strategies. Celerion’s integrated service spans the research process for small and large molecule drugs from lead identification through clinical proof-of-concept - all the way to full clinical development.
Operations are strategically located in:
Lincoln, NE, USA (Corporate Headquarters)
Philadelphia, PA, USA
Phoenix, AZ, USA
Richmond, VA, USA
Montreal, QC, CA
Belfast, Northern Ireland, UK
Prague, Czech Republic
Seoul, South Korea
Please visit Celerion's Resources page to download white papers, presentations, scientific posters, and industry articles.